Diprenorphine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Diprenorphine.png | |
| Diprenorphine
| |
| Systematic (IUPAC) name | |
| (5α,7α)-17-(Cyclopropylmethyl) -4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy -α,α-dimethyl-6,14-ethenomorphinan-7-methanol | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C26H35NO4 |
| Mol. mass | 425.56 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Diprenorphine | |
|
Articles | |
|---|---|
|
Most recent articles on Diprenorphine Most cited articles on Diprenorphine | |
|
Media | |
|
Powerpoint slides on Diprenorphine | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Diprenorphine at Clinical Trials.gov Trial results on Diprenorphine Clinical Trials on Diprenorphine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Diprenorphine NICE Guidance on Diprenorphine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Diprenorphine Discussion groups on Diprenorphine Patient Handouts on Diprenorphine Directions to Hospitals Treating Diprenorphine Risk calculators and risk factors for Diprenorphine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Diprenorphine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Diprenorphine (Revivon, M5050) is an opiate antagonist[1] used to reverse the effects of the super-potent opioid analgesics such as etorphine and carfentanil that are used for tranquilizing large animals in veterinary medicine.
Diprenorphine is the strongest opiate antagonist that is commercially available (some 100 times more potent as an antagonist than nalorphine),[1] and is used for reversing the effects of very strong opioids for which the binding affinity is so high that naloxone does not effectively or reliably reverse the narcotic effects.[1] These super-potent opioids are not used in humans because the dose for a human is so small that it would be difficult to measure properly, so there is an excessive risk of overdose leading to fatal respiratory depression. However conventional opioid derivatives are not strong enough to rapidly tranquilize large animals such as elephants and rhinos, so drugs such as etorphine or carfentanil are available for this purpose.
Diprenorphine is considered the specific antagonist for etorphine and carfentanil,[1] and is normally used to remobilise animals once veterinary procedures have been completed,[1] however it may also be used on humans in the event that they are accidentally exposed to etorphine or carfentanil, for instance if someone working with large animals suffered a needlestick injury with a dart from a tranquiliser dart gun that was loaded with etorphine or carfentanil, they would be given diprenorphine as an antidote.
In theory diprenorphine could also be used as an antidote for treating overdose of certain opioid derivatives which are used in humans, such as buprenorphine, for which the binding affinity is so high that naloxone does not reliably reverse the narcotic effects. However diprenorphine is not generally available in hospitals, instead a vial of diprenorphine is supplied with the etorphine or carfentanil specifically for reversing the effects of these drugs, so use of diprenorphine for treating buprenorphine overdose is not carried out in practice although it would work in theory.
References
WikiDoc Research Resources for Diprenorphine (Click show to right to view) | |
|---|---|
| Articles on Diprenorphine | Most recent articles on Diprenorphine • Most cited articles on Diprenorphine • Review articles on Diprenorphine • Articles on Diprenorphine in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Diprenorphine | Powerpoint slides on Diprenorphine • Images of Diprenorphine • Photos of Diprenorphine • Podcasts & MP3s on Diprenorphine • Videos on Diprenorphine |
| Evidence Based Medicine Regarding Diprenorphine | Cochrane Collaboration on Diprenorphine • Bandolier on Diprenorphine • TRIP on Diprenorphine |
| Cost Effectiveness of Diprenorphine | Cost Effectiveness of Diprenorphine |
| Clinical Trials Involving Diprenorphine | Ongoing Trials on Diprenorphine at Clinical Trials.gov • Trial results on Diprenorphine • Clinical Trials on Diprenorphine at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Diprenorphine | US National Guidelines Clearinghouse on Diprenorphine • NICE Guidance on Diprenorphine • NHS PRODIGY Guidance • FDA on Diprenorphine • CDC on Diprenorphine |
| Textbook Information on Diprenorphine | Books and Textbook Information on Diprenorphine |
| Pharmacology Resources on Diprenorphine | Dosing of Diprenorphine • Drug interactions with Diprenorphine • Side effects of Diprenorphine • Allergic reactions to Diprenorphine • Overdose information on Diprenorphine • Carcinogenicity information on Diprenorphine • Diprenorphine in pregnancy • Pharmacokinetics of Diprenorphine • |
| Genetics, Pharmacogenomics, and Proteinomics of Diprenorphine | Genetics of Diprenorphine • Pharmacogenomics of Diprenorphine • Proteomics of Diprenorphine |
| Newstories on Diprenorphine | Diprenorphine in the news • Be alerted to news on Diprenorphine • News trends on Diprenorphine |
| Commentary on Diprenorphine | Blogs on Diprenorphine |
| Patient Resources on Diprenorphine | Patient resources on Diprenorphine • Discussion groups on Diprenorphine • Patient Handouts on Diprenorphine • Directions to Hospitals Treating Diprenorphine • Risk calculators and risk factors for Diprenorphine |
| Healthcare Provider Resources on Diprenorphine | Symptoms of Diprenorphine • Causes & Risk Factors for Diprenorphine • Diagnostic studies for Diprenorphine • Treatment of Diprenorphine |
| Continuing Medical Education (CME) Programs on Diprenorphine | CME Programs on Diprenorphine |
| International Resources on Diprenorphine | Diprenorphine en Espanol • Diprenorphine en Francais |
| Business Resources on Diprenorphine | Diprenorphine in the Marketplace • Patents on Diprenorphine |
| Informatics Resources on Diprenorphine | List of terms related to Diprenorphine |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

